Kura Oncology (NASDAQ:KURA) Price Target Raised to $16.00 at UBS Group

Kura Oncology (NASDAQ:KURA) had its target price raised by equities research analysts at UBS Group from $14.00 to $16.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 32.29% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Friday. Wedbush reissued an “outperform” rating and issued a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 5th. Finally, Guggenheim assumed coverage on Kura Oncology in a research note on Thursday, September 4th. They issued a “neutral” rating for the company. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.11.

Kura Oncology Trading Up 13.2%

Shares of Kura Oncology stock traded up $1.42 during trading on Friday, reaching $12.10. 3,184,938 shares of the company were exchanged, compared to its average volume of 1,583,286. The business has a 50-day moving average price of $9.40 and a 200-day moving average price of $7.44. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.88 and a beta of 0.35. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $16.68.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Sell-side analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In related news, COO Kathleen Ford sold 6,892 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $61,614.48. Following the completion of the transaction, the chief operating officer directly owned 63,375 shares of the company’s stock, valued at approximately $566,572.50. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,541 shares of the stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $40,596.54. Following the transaction, the senior vice president owned 109,829 shares of the company’s stock, valued at approximately $981,871.26. This trade represents a 3.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 78,058 shares of company stock valued at $697,839 over the last quarter. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL boosted its position in Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after acquiring an additional 5,186,660 shares during the last quarter. EcoR1 Capital LLC boosted its holdings in Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after purchasing an additional 1,559,702 shares during the last quarter. Armistice Capital LLC boosted its holdings in Kura Oncology by 13.3% during the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after purchasing an additional 772,000 shares during the last quarter. Qube Research & Technologies Ltd grew its position in Kura Oncology by 63.0% in the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Kura Oncology by 407.8% in the 1st quarter. AQR Capital Management LLC now owns 760,332 shares of the company’s stock valued at $5,018,000 after buying an additional 610,604 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.